⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619244 | 1.00 | — | — | |
| SCHEMBL11911402 | 0.77 | — | — | |
| SCHEMBL1619198 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL1619196 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL8776070 | 0.74 | — | — | |
| SCHEMBL8776073 | 0.74 | — | — | |
| SCHEMBL3286849 | 0.74 | — | — | |
| SCHEMBL3286850 | 0.74 | — | — | |
| SCHEMBL9284610 | 0.74 | — | — | |
| SCHEMBL7037053 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205908-A1 | SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2023-11-02 | — | — | WO | disclosed |
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| EP-1472209-B1 | LIPOXIN A4 ANALOGS | BAYER SCHERING PHARMA AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20050113443-A1 | Modulation of airway inflammation in patients with cystic fibrosis and related diseases | KARP CHRISTOPHER L (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004110426-A1 | MODULATION OF AIRWAY INFLAMMATION IN PATIENTS WITH CYSTIC FIBROSIS AND RELATED DISEASES | PETASIS NICOS A (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6831186-B2 | Antiinflammatory agents; autoimmune disease | SCHERING AKTIENGESELLSCHFT (DE) | 2004-12-14 | — | — | US | disclosed |
| EP-1472209-A2 | LIPOXIN A4 ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20040162433-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | US | disclosed |
| US-20030139376-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003040080-A2 | LIPOXIN A4 ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-15 | — | — | WO | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |